Iovance Biotherapeutics Company

Iovance Biotherapeutics develops T-cell-based immunotherapy products for the treatment of cancer.
Technology: CAR-T, CAR-T therapy, Cell-based gene therapy
Industry: Public
Headquarters: New York, New York, United States
Founded Date: 2007-01-01
Employees Number: 251-500
Funding Status: IPO
Investors Number: 4
Total Funding: 1215400000
Estimated Revenue: $50M to $100M
Last Funding Date: 2020-05-27
Last Funding Type: Post-IPO Equity

Visit Website
Register and Claim Ownership